Global Use of Nordic Real-World Evidence: A Systematic Review of Published Literature and HTA Submissions

Author(s)

Kaushik P1, Toresson Grip E2, Lueza B2, Arya S1, Singh N1, Nanda S1, Grover R1, Afaque A1, Syal K1
1Quantify Research, Sahibzada Ajit Singh Nagar (Mohali), PB, India, 2Quantify Research, Stockholm, Sweden

OBJECTIVES: Nordic real-world data (RWD) offers unique and globally un-paralleled opportunities in health registry-based research. It provides virtually complete follow-up and exact censoring information on lives and health of all citizens with essentially unlimited possibilities for linkage of data on patient-level. Ability to utilize this RWD for submission to healthcare authorities globally may help to accelerate access to treatments in case of scarcity of RWD. This systematic review aimed to identify evidence indicating a global usage of Nordic RWD.

METHODS: A systematic review adhering to PRISMA guidelines was performed to identify any publications/submissions recommending or exhibiting a global usage of RWD from Denmark, Finland, Norway, or Sweden. All searches were run on 9-June-2023 and included Embase® (from inception of database), ad-hoc Google searches, and Health technology assessment (HTA) submissions to NICE and CADTH (January-2021 and onwards).

RESULTS: A total of 1785 records from Embase®, and 234/475 submissions from NICE/CADTH databases were retrieved. Deduplication and screening led to inclusion of 27 publications and 29 submissions (19/10: NICE/CADTH). In-depth analysis of publications revealed the top three regions utilizing the Nordic RWD as Europe (68.1%), the US (22.7%), and Israel (9%). National administrative and disease registers (63.1%) were the most reported RWD type and oncology (31.5%) was the most common disease area. RWD was most frequently utilized from Sweden (75.8%) and Denmark (59.2%); while utility/QoL (37.9%) and safety (34.7%) were the most common outcomes as per the evidence from HTAs and publications, respectively.

CONCLUSIONS: The evidence from the current review indicates global acceptability of Nordic RWD in various settings and disease areas. This encourages considering Nordic RWD in support of HTA, regulatory applications and post-approval requirements, globally. However, there exists vast untapped potential requiring additional collaborative efforts between stakeholders in industry, data holders and regulatory authorities to reap complete benefits of the Nordic RWD.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

RWD142

Topic

Health Policy & Regulatory, Health Technology Assessment, Real World Data & Information Systems, Study Approaches

Topic Subcategory

Decision & Deliberative Processes, Distributed Data & Research Networks, Literature Review & Synthesis, Reimbursement & Access Policy

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×